Uroplakin-2 (UPK2) is a highly specific transmembrane glycoprotein primarily expressed in the urothelium. As a crucial structural component of the urinary bladder's apical surface, UPK2 forms a specialized membrane barrier. In oncology, UPK2 serves as an exceptionally lineage-specific biomarker for urothelial carcinoma, making it a premier target for antibody-drug conjugates (ADCs), CAR-T cell therapies, and bispecific antibodies aimed at bladder cancer.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for UPK2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | UPK2 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. |
View UPK2 Products |
| Gene Delivery | UPK2 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Conformation preservation. |
View UPK2 Products |
| Benchmark Ab | Anti-UPK2 Recombinant Antibody Recombinant positive control for binding and internalization assays. |
View UPK2 Products |
| Validator | UPK2 siRNA Set For knockdown verification and target specificity validation. |
View UPK2 Products |
| Related Target A | UPK1A Obligate heterodimerization partner of UPK2; critical for native conformational epitope presentation. |
View UPK1A Products |
| Related Target B | UPK3A Co-expressed urothelial differentiation marker; useful for multi-target specificity panels. |
View UPK3A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational Epitope Preservation (Heterodimerization) | Lentivirus Premade Particles for stable cell line construction to allow native assembly with UPK1A. |
| Selectivity Screening vs. Uroplakin Family | Recombinant UPK1A, UPK1B, and UPK3A proteins strictly verified by Mass Spectrometry. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies available as assay controls. |
| Target Specificity & Knockdown Verification | Sequence-verified siRNA pools for functional validation and off-target screening. |
Live UPK2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic development targeting UPK2 is rapidly gaining momentum. While historically utilized as an immunohistochemical diagnostic marker for metastatic urothelial carcinoma, its strict tissue distribution has positioned UPK2 as an attractive target for tumor-selective therapeutics. The race for UPK2 therapeutics is intensifying, with major players shifting focus from traditional mAbs to antibody-drug conjugates (ADCs) and CAR-T cell therapies. As first-generation therapies reach the clinic, the next wave of R&D is targeting engineered bispecific antibodies and combination regimens to overcome the immunosuppressive microenvironment of advanced bladder cancer.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | Biotech Innovators, Academic Medical Centers | Metastatic Urothelial Carcinoma, Bladder Cancer | Internalization Assay (Need high-purity ECD-Fc and stable cell lines) |
| CAR-T | Cell Therapy Developers | Refractory Bladder Cancer | Target Density & Specificity Assay (Need Lentivirus for stable overexpressing lines) |
| Bispecific / T-Cell Engager | Oncology Biopharma | Advanced Solid Tumors (Urothelium-derived) | Heterodimer Validation (Need cross-reactive antigens and ortholog proteins) |